Drug intelligence / Profile preview

Fangbai Granule

Development stage: Unknown
Lead developer: Chongqing City Hospital of Traditional Chinese Medicine
Administration: Oral

Overview

Fangbai Granule is a Traditional Chinese Medicine (TCM) formulation developed by the Chongqing Hospital of Traditional Chinese Medicine for the treatment of vitiligo. It is primarily used to reduce the recurrence rate of the disease and promote repigmentation in affected skin areas. As a botanical-based combination therapy, its therapeutic effects are attributed to the synergistic action of multiple herbal components, which are thought to modulate the local immune environment and stimulate melanocyte activity. The drug is currently being evaluated in clinical trials (e.g., ChiCTR2200056417) to establish its efficacy and safety profile in maintaining stability and preventing relapse in patients with vitiligo.

Brand names: Fangbai Granule
Other names: Fangbai Keli方白颗粒

Beyond the preview

Go deeper on Fangbai Granule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fangbai Granule.

Explore the full profile